Todd Christopher Longsworth Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Todd Christopher Longsworth.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Todd Christopher Longsworth. Todd Christopher Longsworth is General Counsel in Novocure Ltd ($NVCR).
Latest Insider Trading Transactions of Todd Christopher Longsworth
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 10 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 130.81 | 2,404 | 314,458 | 67,714 | 70.1 K to 67.7 K (-3.43 %) |
Mar 08 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 137.55 | 3,084 | 424,217 | 70,118 | 73.2 K to 70.1 K (-4.21 %) |
Mar 04 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 153.09 | 19,004 | 2,909,322 | 19,004 | |
Mar 04 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 0.00 | 10,342 | 0 | 73,202 | 62.9 K to 73.2 K (+16.45 %) |
Mar 04 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 152.05 | 2,355 | 358,085 | 62,860 | 65.2 K to 62.9 K (-3.61 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 14.37 | 36,396 | 523,011 | 0 | |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 179.30 | 1,200 | 215,161 | 59,660 | 60.9 K to 59.7 K (-1.97 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 178.50 | 900 | 160,648 | 60,860 | 61.8 K to 60.9 K (-1.46 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 177.33 | 2,841 | 503,797 | 61,760 | 64.6 K to 61.8 K (-4.40 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 176.22 | 400 | 70,486 | 64,601 | 65 K to 64.6 K (-0.62 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.28 | 2,200 | 385,614 | 65,001 | 67.2 K to 65 K (-3.27 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 174.06 | 2,502 | 435,506 | 67,201 | 69.7 K to 67.2 K (-3.59 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 173.10 | 1,700 | 294,270 | 69,703 | 71.4 K to 69.7 K (-2.38 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.90 | 11,985 | 2,060,257 | 71,403 | 83.4 K to 71.4 K (-14.37 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.32 | 4,826 | 826,781 | 83,388 | 88.2 K to 83.4 K (-5.47 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.93 | 2,542 | 431,970 | 88,214 | 90.8 K to 88.2 K (-2.80 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.19 | 1,800 | 304,549 | 90,756 | 92.6 K to 90.8 K (-1.94 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 167.77 | 3,500 | 587,209 | 92,556 | 96.1 K to 92.6 K (-3.64 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 179.37 | 900 | 161,431 | 96,056 | 97 K to 96.1 K (-0.93 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 178.68 | 1,000 | 178,675 | 96,956 | 98 K to 97 K (-1.02 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 177.31 | 2,200 | 390,071 | 97,956 | 100.2 K to 98 K (-2.20 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.98 | 400 | 70,392 | 100,156 | 100.6 K to 100.2 K (-0.40 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.14 | 1,700 | 297,731 | 100,556 | 102.3 K to 100.6 K (-1.66 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 173.88 | 1,600 | 278,205 | 102,256 | 103.9 K to 102.3 K (-1.54 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 172.95 | 1,300 | 224,838 | 103,856 | 105.2 K to 103.9 K (-1.24 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.86 | 10,110 | 1,737,494 | 105,156 | 115.3 K to 105.2 K (-8.77 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.18 | 2,761 | 472,639 | 115,266 | 118 K to 115.3 K (-2.34 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.76 | 2,148 | 364,644 | 118,027 | 120.2 K to 118 K (-1.79 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 168.80 | 800 | 135,043 | 120,175 | 121 K to 120.2 K (-0.66 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 167.76 | 2,499 | 419,235 | 120,975 | 123.5 K to 121 K (-2.02 %) |
Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 14.37 | 36,396 | 523,011 | 123,474 | 87.1 K to 123.5 K (+41.80 %) |
Jul 08 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 50.41 | 325 | 16,382 | 87,078 | 86.8 K to 87.1 K (+0.37 %) |
Mar 05 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 69.37 | 37,058 | 2,570,713 | 37,058 | |
Mar 05 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 0.00 | 19,220 | 0 | 89,252 | 70 K to 89.3 K (+27.44 %) |
Mar 02 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 5,556 | 0 | 5,555 | |
Mar 02 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 72.22 | 2,643 | 190,864 | 70,032 | 72.7 K to 70 K (-3.64 %) |
Mar 02 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 79.45 | 5,556 | 441,424 | 72,675 | 67.1 K to 72.7 K (+8.28 %) |
Feb 26 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 21,666 | 0 | 0 | |
Feb 26 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 81.16 | 8,482 | 688,365 | 67,119 | 75.6 K to 67.1 K (-11.22 %) |
Feb 26 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 88.26 | 21,666 | 1,912,241 | 75,601 | 53.9 K to 75.6 K (+40.17 %) |
Jan 13 2020 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 52.58 | 35 | 1,840 | 53,935 | 53.9 K to 53.9 K (+0.06 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 21.15 | 30,414 | 643,256 | 86,513 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 56,874 | 406,649 | 97,799 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,632 | 78,167 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 59,520 | 399,974 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.86 | 1,200 | 107,828 | 53,900 | 55.1 K to 53.9 K (-2.18 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.86 | 2,900 | 257,703 | 55,100 | 58 K to 55.1 K (-5.00 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.18 | 14,888 | 1,312,794 | 58,000 | 72.9 K to 58 K (-20.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.86 | 11,426 | 992,440 | 72,888 | 84.3 K to 72.9 K (-13.55 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.15 | 30,414 | 643,256 | 84,314 | 53.9 K to 84.3 K (+56.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.87 | 4,031 | 362,262 | 53,900 | 57.9 K to 53.9 K (-6.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.97 | 7,869 | 700,129 | 57,931 | 65.8 K to 57.9 K (-11.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.22 | 24,083 | 2,124,482 | 65,800 | 89.9 K to 65.8 K (-26.79 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.95 | 20,891 | 1,816,556 | 89,883 | 110.8 K to 89.9 K (-18.86 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 56,874 | 406,649 | 110,774 | 53.9 K to 110.8 K (+105.52 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.97 | 400 | 35,988 | 53,900 | 54.3 K to 53.9 K (-0.74 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.94 | 929 | 82,622 | 54,300 | 55.2 K to 54.3 K (-1.68 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.19 | 6,065 | 534,897 | 55,229 | 61.3 K to 55.2 K (-9.89 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.88 | 4,238 | 368,206 | 61,294 | 65.5 K to 61.3 K (-6.47 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,632 | 78,167 | 65,532 | 53.9 K to 65.5 K (+21.58 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.90 | 2,300 | 206,759 | 53,900 | 56.2 K to 53.9 K (-4.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.82 | 6,616 | 587,620 | 56,200 | 62.8 K to 56.2 K (-10.53 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.17 | 28,340 | 2,498,766 | 62,816 | 91.2 K to 62.8 K (-31.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.85 | 22,264 | 1,933,539 | 91,156 | 113.4 K to 91.2 K (-19.63 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 59,520 | 399,974 | 113,420 | 53.9 K to 113.4 K (+110.43 %) |
Jul 09 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 27.81 | 696 | 19,357 | 53,900 | 53.2 K to 53.9 K (+1.31 %) |
Mar 26 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 47.04 | 29,969 | 1,409,742 | 29,969 | |
Mar 26 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 0.00 | 16,369 | 0 | 53,204 | 36.8 K to 53.2 K (+44.44 %) |
Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 5,556 | 0 | 11,111 | |
Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 53.68 | 2,368 | 127,114 | 36,835 | 39.2 K to 36.8 K (-6.04 %) |
Mar 01 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 52.90 | 5,556 | 293,912 | 39,203 | 33.6 K to 39.2 K (+16.51 %) |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 11,874 | 84,899 | 154,673 | |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 166,547 | |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 50.15 | 11,874 | 595,481 | 21,305 | 33.2 K to 21.3 K (-35.79 %) |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 11,874 | 84,899 | 33,179 | 21.3 K to 33.2 K (+55.73 %) |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 48.15 | 15,000 | 722,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 181,547 | |
Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 45.15 | 15,000 | 677,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 196,547 | |
Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 40.15 | 15,000 | 602,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
Jul 10 2018 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 17.26 | 1,231 | 21,241 | 21,305 | 20.1 K to 21.3 K (+6.13 %) |
Mar 01 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 0.00 | 16,667 | 0 | 16,667 | |
Mar 01 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | A | 21.15 | 121,655 | 2,573,003 | 121,655 | |
Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 0.00 | 21,667 | 0 | 43,333 | |
Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 19.83 | 6,591 | 130,686 | 20,074 | 26.7 K to 20.1 K (-24.72 %) |
Feb 26 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.55 | 21,667 | 466,924 | 26,665 | 5 K to 26.7 K (+433.51 %) |
Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,630 | 78,154 | 71,152 | |
Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 24.00 | 11,630 | 279,120 | 4,998 | 16.6 K to 5 K (-69.94 %) |
Jan 31 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,630 | 78,154 | 16,628 | 5 K to 16.6 K (+232.69 %) |
Jan 10 2018 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 15.05 | 166 | 2,497 | 4,998 | 4.8 K to 5 K (+3.44 %) |
Jul 07 2017 | NVCR | Novocure Ltd | Longsworth Todd Christopher | General Counsel | Grant | A | 6.67 | 2,810 | 18,751 | 4,832 | 2 K to 4.8 K (+138.97 %) |
Page: 1